GH Research PLC

GHRS chart

GH Research PLC news

• Psychedelic pioneer Compass files for FDA approval as rivals close in

  Drug Discovery & Development · Nov 9, 8:22 PM EST

• GSW Immobilien (HMSE:GIB) Stock Looks Fairly Valued On Balance Sheet Questions

  Yahoo Finance · Nov 8, 9:14 PM EST

• GH Research PLC Financial Statements – NASDAQ:GHRS

  TradingView · Nov 7, 10:16 PM EST

• GH Research set to report earnings amid Phase 3 preparation push

  Investing.com Nigeria · Nov 4, 1:33 PM EST

• GHRS Q3'26 Earnings: EPS estimate is (0.31) USD

  TradingView · Nov 4, 7:01 AM EST

• COMPASS Pathways rebounds on earnings after selloff driven by rival’s NDA submission

  TradingView · Nov 3, 8:41 AM EST

• GH Research (GHRS) Stock Looks Fully Priced As Book Value Questions Linger

  Yahoo Finance · Nov 1, 6:24 PM EST

• GH Research (GHRS) Stock May Look Stretched As Book Value Trails Price

  Yahoo Finance · Oct 18, 6:07 PM EDT

• Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight

  Yahoo Finance · Aug 25, 10:31 AM EDT

• GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

  Yahoo Finance · Aug 6, 7:00 AM EDT

• Is GH Research (GHRS) Trading At A Premium To Fair Value?

  Yahoo Finance · Aug 2, 2:09 PM EDT

• CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

  stocktwits.com · Jul 27, 10:38 AM EDT

GH Research PLC key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-K6-K2026-10-09
• 6-KReport (foreign issuer)2026-09-11
• 6-K6-K2026-08-06
• 6-K6-K2026-06-26
• 6-K6-K2026-06-04
• 6-K6-K2026-05-21
• 6-K6-K2026-05-14
• 6-K6-K2026-05-14
• 6-K6-K2026-05-13
• 6-K6-K2026-05-13
• 6-K6-K2026-04-30
• 6-K6-K2026-03-25

About GH Research PLC

Ticker

GHRS (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Dublin 2, Ireland

Incorporated in

Ireland

Fiscal year end

December 31

SEC CIK

1855129

Frequently asked questions